Irisin levels in relation to metabolic and liver functions in Egyptian patients with metabolic syndrome

Canadian Journal of Physiology and Pharmacology

Volumn 94, Issue 4, 2016, Pages 359-362

  Rizk, Fatma H ^a   Elshweikh, Samah A ^a   El Naby, Amira Y Abd ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Fatty liver; Irisin; Metabolic syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; INSULIN; IRISIN; TRIACYLGLYCEROL; FIBRONECTIN; FNDC5 PROTEIN, HUMAN;

ADULT; ARTICLE; BIOCHEMICAL ANALYSIS; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EGYPTIAN; ENDOCRINE FUNCTION TEST; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEPATIC CLEARANCE; HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE INDEX; HORMONE BLOOD LEVEL; HUMAN; HYPERTRANSAMINASEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC REGULATION; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; EGYPT; HOMEOSTASIS; LIVER; NONALCOHOLIC FATTY LIVER; PHYSIOLOGY;

ADULT; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; EGYPT; FEMALE; FIBRONECTINS; GLUCOSE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; TRIGLYCERIDES;

EID: 84964034566     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2015-0371     Document Type: Article

References (19)

1. Al-Daghri, N.M., Alkharfy, K.M., Rahman, S., Amer, O.E., Vinodson, B., Sabico, S., et al. 2013. Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects. Eur. J. Clin. Invest. 44: 119-124. doi:10.1111/eci.12196. PMID: 24188288.
2. Boström, P., Wu, J., Jedrychowski, M.P., Korde, A., Ye, L., Lo, J.C., et al. 2012. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature, 481: 463-468. doi:10.1038/nature10777. PMID:22237023.
3. Chen, J.Q., Huang, Y.Y., Gusdon, A.M., and Qu, S. 2015. Irisin: a new molecular marker and target in metabolic disorder. Lipids Health Dis. 14: 2. doi:10.1186/ 1476-511X-14-2. PMID:25588692.
4. Choi, Y.K., Kim, M.K., Bae, K.H., Seo, H.A., Jeong, J.Y., Lee, W.K., et al. 2013. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res. Clin. Pract. 100(1): 96-101. doi:10.1016/j.diabres.2013.01.007. PMID:23369227.
5. Ebert, T., Focke, D., Petroff, D., Wurst, U., Richter, J., Bachmann, A., et al. 2014. Serum levels of the myokine irisin in relation to metabolic and renal function. Eur. J. Endocrinol. 170(4): 501-506. doi:10.1530/EJE-13-1053. PMID: 24399249.
6. Fisher, F.M., Kleiner, S., Douris, N., Fox, E.C., Mepani, R.J., Verdeguer, F., et al. 2012. FGF21 regulates PGC-1β and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 26: 271-281. doi:10.1101/gad.177857.111. PMID: 22302939.
7. Fossati, P., and Prencipe, L. 1982. Triglycerides determination after enzymatic hydrolysis. Clin. Chem. 28: 2077-2080. PMID:6812986.
8. Grundy, S.M., Brewer, H.B., Cleeman, J.I., Smith, S.C., and Lenfant, C. 2004. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 109: 433-438. doi:10.1161/01.CIR.0000111245.75752.C6. PMID:14744958.
9. Jung, U.J., and Choi, M.S. 2014. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int. J. Mol. Sci. 15(4): 6184-6223. doi:10.3390/ijms15046184. PMID:24733068.
10. Krefetz, R.G., and McMillin, G.A. 2005. Enzymes. In Clinical chemistry principles, procedures, correlations, 5th ed. Edited by M.L. Bishop, E.P. Fody, and L. Schoeff. United States of America, Lippincott Williams & Wilkins, pp. 250-251.
11. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., and Turner, R.C. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28: 412-419. doi:10.1007/BF00280883. PMID:3899825.
12. Pardo, M., Crujeiras, A.B., Amil, M., Aguera, Z., Jimenez-Murcia, S., Banos, R., et al. 2014. Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index. Int. J. Endocrinol. 2014: 1-9. doi:10.1155/2014/857270. PMID:24864142.
13. Park, K.H., Zaichenko, L., Brinkoetter, M., Thakkar, B., Sahin-Efe, A., Joung, K.E., et al. 2013. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J. Clin. Endocrinol. Metab. 98(12): 4899-4907. doi:10.1210/jc. 2013-2373. PMID:24057291.
14. Ronis, M.J.J., Baumgardner, J.N., Marecki, J.C., Wu, L.H.X, Shankar, K., Cleves, M.A., et al. 2012. Dietary fat source alters hepatic gene expression profile and determines the type of liver pathology in rats overfed via total enteral nutrition. Physiol. Genomics, 44: 1073-1089. doi:10.1152/ physiolgenomics.00069.2012. PMID:22991207.
15. Sanchis-Gomar, F., Alis, R., Pareja-Galeano, H., Sola, E., Victor, VM, Rocha, M., et al. 2014. Circulating irisin levels are not correlated with BMI, age, and other biological parameters in obese and diabetic patients. Endocrine, 46(3): 674-677. doi:10.1007/s12020-014-0170-9. PMID:24510629.
16. Tietz, N.W. 1986. Determination of blood glucose, Text book of clinical chemistry. WB Saunders. Co. London, Philadelphia, pp. 796.
17. Yan, B., Shi, X., Zhang, H., Pan, L., Ma, Z., Liu, S., et al. 2014. Association of serum irisin with metabolic syndrome in obese Chinese adults. PLoS One, 9(4): e94235. doi:10.1371/journal.pone.0094235. PMID:24709991.
18. Zhang, Y., and Scarpace, P.J. 2006. The role of leptin in leptin resistance and obesity. Physiol. Behav. 88: 249-256. doi:10.1016/j.physbeh.2006.05.038. PMID:16782141.
19. Zhang, Y., Li, R., Meng, Y., Li, S., Donelan, W., Zhao, Y., et al. 2014. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes, 63: 514-525. doi:10.2337/db13-1106. PMID:24150604.